Drug Trial Radar · NCT02947932
Oral Resveratrol to Prevent Post-ERCP Pancreatitis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,700
Planned (sponsor's estimate)
Start
Dec 2016
Primary completion
Mar 2018
Study completion Sep 2018
Sponsor
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. However, the risk factors of PEP is not fully clear. Additionally, the complication of NSAID use lead to some serious physical problem bleeding. Therefore, the exclusive criteria for limiting the NSAID use is including allergy, gastrointestinal haemorrhage ,presence of coagulopathy or received anticoagulation therapy. Previous study showed that another natural compound, resveratrol, owns similar biological effect with NSAID. Firstly, it could inhibit the inflammatory response on in vivo model through inhibition of COX and IL-6 etc. Secondly, it could not influence the level of platelet and coagulation, which means safer than NSAID. Thirdly, numerous studies showed that resveratrol could effectively the progression of severe acute pancreatitis. According to data, we design the project. The purpose of this study is to determine whether oral resveratrol pre-ERCP is effective on control of Post-ERCP pancreatitis.
Conditions
- Pancreatitis, Acute
- Gastrointestinal Disease
Interventions
ResveratrolDrug
pre-ERCP intervention
IndomethacinDrug
post-ERCP intervention in high risk patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post-ERCP PancreatitisTime frame: 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.